Brief psychotic disorder associated with quarantine and mild COVID-19

BMJ Case Rep. 2020 Dec 16;13(12):e240088. doi: 10.1136/bcr-2020-240088.

Abstract

A 30-year-old man with no significant previous or family psychiatric history became severely anxious about his health after a positive COVID-19 test. Physical symptoms of COVID-19 were mild, with no evidence of hypoxia or pneumonia, throughout his illness. He was admitted to a quarantine facility. He remained highly anxious, and 1 week later, he developed paranoid delusions and auditory hallucinations (his first psychotic episode). He was treated with lorazepam 1 mg four times a day, mirtazapine 30 mg nocte and risperidone 1 mg two times a day. His psychotic symptoms lasted 1 week. He stopped psychiatric medication after 4 weeks and had remained well when reviewed 3 months later. A Diagnostic and Statistical Manual of Mental Disorders fifth edition diagnosis of brief psychotic disorder with marked stressor (brief reactive psychosis) was made. Anxiety about his health and social isolation appeared the main aetiological factors but an inflammatory component cannot be excluded. The case highlights that first episode psychosis can be associated with mild COVID-19.

Keywords: COVID-19; psychiatry (drugs and medicines); psychotic disorders (incl schizophrenia).

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Anxiety Agents / administration & dosage
  • Antipsychotic Agents / administration & dosage
  • Anxiety Disorders / drug therapy
  • Anxiety Disorders / psychology*
  • COVID-19 / psychology*
  • Humans
  • Lorazepam / administration & dosage
  • Male
  • Mirtazapine / administration & dosage
  • Pandemics
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / psychology*
  • Qatar
  • Quarantine / psychology
  • Risperidone / administration & dosage
  • SARS-CoV-2

Substances

  • Anti-Anxiety Agents
  • Antipsychotic Agents
  • Mirtazapine
  • Risperidone
  • Lorazepam